DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00993304

CompletedPhase 1

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 18.5-40•HbA1c 6.5-10%

Primary endpoint

•AUC0-8h (triglyceride), the AUC of triglyceride- in the interval 0-8 hours

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00993304
Org study IDNN2211-3534
Secondary ID2008-003229-18
Secondary IDU1111-1111-9161WHO

Timeline

Milestones

Study first posted2009-10-12estimated
Last update posted2017-01-26estimated
Study start2009-10 (month precision)
Primary completion2010-12actual (month precision)
Study completion2010-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Subjects with type 2 diabetes mellitus (diet and exercise treated, or treated with specific oral antidiabetics (metformin, sulfonylureas and glinides) mono- or combination therapy) diagnosed at least 3 months previously
•BMI between 18.5 and 40 kg/m2
•HbA1c between 6.5 and 10.0% both inclusive

Exclusion criteria

•Known or suspected allergy to trial products or related products
•Previous participation in this trial (randomised). Re-screening of screening failures is allowed only once
•Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptives are defined as combination oral contraceptives (OC), hormonal intra uterine devices (IUDs), implants and injectables; for Germany, a condom for the male partner must be used in combination with OC, IUD, implant or injectables for the duration of the trial and for 30 days following the last dose of trial medication) if not sterile or post-menopausal
•The receipt of any investigational drug within 3 months prior to this trial
•Previous insulin treatment (short-term insulin treatment of up to 7 days are exempted if this has occurred no later than 3 months prior to screening).
•Cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder (except type 2 diabetes)
•Clinically significant active cardiovascular disease including history of myocardial infarction (heart attack) within the past 6 months and/or heart failure at the discretion of the Investigator.
•History of alcoholism or drug abuse during the last 12 months
•Blood donation within the last 3 months. Plasma donation within the last month.
•Additional exclusion criteria for Germany: Male subjects who are sexually active and have partners who are or could be pregnant, not using a barrier method of contraception (e.g. condom) for the duration of the trial and for 30 days following the last dose of trial medication

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Cardiometabolic biomarkers
1
Safety / tolerability / PK
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Glucose, insulin, C-peptide and glucagon: AUC0-8 hours after meal with a high fat content

Time frame:after 3 weeks of treatment

concentration, descriptive

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint/low confidence

FFA (Free Fatty Acid), VLDL (Very Low Density), and apoB48: AUC0-8 hours after meal with a high fat content

Time frame:after 3 weeks of treatment

AUC₀–∞

concentration, descriptive

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content

Time frame:after 3 weeks of treatment

AUC₀–∞

concentration, descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.